Boehringer Ingelheim Launches New Business Development Initiative
Boehringer Ingelheim Animal Health has launched a new business development initiative delivered by its Veterinary Development team, which will support practices in implementing evidence-based veterinary medicine and help grow their businesses.
Boehringer’s Veterinary Development Partners are all experienced small animal clinicians who are equipped to work with veterinary clinics and implement independent clinical audits on their behalf. Clinical audit provides a methodology to apply evidence-based veterinary medicine and is widely considered within human healthcare to be the most effective way to improve and optimise patient care. Clinical audit is a ‘no-blame’ process which helps engage all clinic staff in a culture of continuous improvement and education.
“At Boehringer Ingelheim we believe in helping our customers do the right thing. Clinical audit provides a well-established framework to help us do exactly that,” comments Rebecca Maher, Veterinary Affairs Lead at Boehringer Ingelheim. “Importantly though, our Veterinary Development Partners don’t just identify gaps through the audit process, but they also partner with our customers to help them identify and implement plans and solutions which enable them to close those gaps, delivering the best clinical outcomes for patients, promoting high staff morale and pet owner satisfaction, and of course helping our customers’ businesses thrive,”
To find out more about the services which Boehringer Ingelheim’s Veterinary Development team can offer your clinic, contact your local Boehringer Territory Manager.
Photo shows: The Boehringer Ingelheim Veterinary Development Team (from left to right): David Cahill MVB LLB MRCVS, Charlotte Jennings BVetMed MRCVS and Janet Winter BVMS CertVR CertCIM MRCVS.
For further press information, please contact:
Jessica Henman at MG Communications on 01488 683862 or email firstname.lastname@example.org
An educational service from Boehringer Ingelheim Animal Health UK Ltd (“BI”). Further information available from BI, RG12 8YS, UK. ©2019. All rights reserved. Date of preparation: Jun 2019. AHD12524. Use Medicines Responsibly.
More from Boehringer Ingelheim
- Boehringer Ingelheim runs Broadline lunch and learn competition
- Boehringer Ingelheim and Global Stem Cell Technology to bring ground-breaking innovation to equine market
- Boehringer launches Equine Endocrine Pioneers Circle webinar
- FEI launches new online equine influenza webinars for equine vets and horse owners
- New name and packaging for Equitop GLME